Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes. The company is preparing to initiate further Phase 2 trials in patients with heart failure and preserved ejection fraction to explore the potential of CBD-based therapy to reduce hospitalization rates and improve quality of life. In parallel, Cardiol is investigating novel cyclic dinucleotide immunomodulators designed to recalibrate the innate immune response in cardiovascular settings.

Headquartered in Toronto, Canada, Cardiol Therapeutics operates multiple clinical and research collaborations across North America and Europe. Founded in 2017 and rebranded in 2019 after acquiring its core CBD assets, the company is led by Executive Chairman Peter Hamilton, a seasoned life-science executive, alongside a management team with deep expertise in drug development, regulatory affairs, and cardiovascular research. Cardiol’s strategy emphasizes translational science and collaborative clinical programs to address critical unmet needs in heart disease.

Key Stats

• Today's Range: $2.10 to $2.24
• 50-Day Range: $0.99 to $2.15
• 52-Week Range: $0.88 to $2.28
• Volume: 2.17 million shs
• Average Volume: 711,759 shs
• Market Capitalization: $251.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Cardiol Therapeutics Stock Analysis - MarketRank™

Cardiol Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 515th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cardiol Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cardiol Therapeutics has a consensus price target of $10.00, representing about 360.8% upside from its current price of $2.17.

Amount of Analyst Coverage

Cardiol Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cardiol Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiol Therapeutics is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiol Therapeutics is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiol Therapeutics has a P/B Ratio of 14.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.11% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardiol Therapeutics has recently increased by 2.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiol Therapeutics does not currently pay a dividend.

Dividend Growth

Cardiol Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Cardiol Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cardiol Therapeutics this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for CRDL on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.25% of the stock of Cardiol Therapeutics is held by insiders.

Percentage Held by Institutions

12.49% of the stock of Cardiol Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/02/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRDL
• CIK: 1702123
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 20
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Cardiol Therapeutics: $10.00
• High Price Target: $11.00
• Low Price Target: $9.00
• Potential Upside/Downside: +360.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.44%
• Return on Assets: -140.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.55
• Quick Ratio: 5.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 14.47

Miscellaneous

• Outstanding Shares: 115,890,000
• Free Float: 109,801,000
• Market Cap: $251.48 million
• Optionable: Not Optionable
• Beta: 0.79